spacer spacer

spacer

Martin Koebel

PUBLICATIONS
  1. Köbel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, Levin Jakobsen AM, Lidang M, Måsbӓck A, Tolf A, Gilks CB, Carlson JW. (2014-03-07). Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology. 64(7),1004
  2. Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, Huntsman DG, Köbel M, Lee CH. (2014-03-01). Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor. Histopathology. 64(4),585
  3. Kommoss S, Gilks CB, Kommoss F, Chow C, Hilpert F, du Bois A, Köbel M, Huntsman DG, Anglesio M, Kalloger SE, Pfisterer J. (2013-11-01). Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. Histopathology. 63(5),704
  4. Hoang LN, McConechy MK, Köbel M, Han G, Rouzbahman M, Davidson B, Irving J, Ali RH, Leung S, McAlpine JN, Oliva E, Nucci MR, Soslow RA, Huntsman DG, Gilks CB, Lee CH. (2013-09-01). Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas. Am J Surg Pathol. 37(9),1421
  5. Koebel M, Kalloger S, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GA, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich KB, Edwards RP, Modugno F, Bunker CH, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, Gilks B, Huntsman DG, Ramus SJ, Goode EL. (2013-07-23). Biomarker-based ovarian carcinoma typing: a histological investigation in the Ovarian Tumor Tissue Analysis consortium. Cancer Epidemiol Biomarkers Prev. 22(10),1677
  6. Sieh W, Köbel M, Longacre TA, Bowtell DD, Defazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ. (2013-07-08). Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 14(9),853
  7. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M; PRACTICAL Consortium, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Ling Woo Y, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Palmieri Weber R, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Anne Rossing M, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Zawiah Omar S, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Mat Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubiński J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Krüger Kjaer S, Kiemeney LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Høgdall CK, Høgdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Dürst M, du Bois A, Dörk T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A, Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA; stralian Ovarian Cancer Study Group; stralian Cancer Study, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, Goode EL, Leigh Pearce C. (2013-03-27). Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun. 4(0),1628
  8. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Köbel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M. (2013-01-02). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 123(1),517
  9. Cipollone JA, Graves ML, Köbel M, Kalloger SE, Poon T, Gilks CB, McNagny KM, Roskelley CD. (2012-03-01). The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. Clin Exp Metastasis. 29(3),239
  10. Milne K, Alexander C, Webb JR, Sun W, Dillon K, Kalloger SE, Gilks CB, Clarke B, Köbel M, Nelson BH. (2012-02-27). Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med. 10(1),33
  11. McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB. (2012-01-27). BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 25(5),740
  12. Gilks CB, Clarke BA, Han G, Köbel M, Longacre T, McCluggage WG, Seidman JD, Shaw P, Soslow RA. (2011-09-01). Letter to the editor regarding 'Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression'. Mod Pathol. 24(9),1281
  13. Köbel M, Turbin D, Kalloger SE, Gao D, Huntsman DG, Gilks CB. (2011-07-01). Biomarker Expression in Pelvic High-grade Serous Carcinoma: Comparison of Ovarian and Omental Sites. Int J Gynecol Pathol. 30(4),366
  14. Anglesio MS, Carey MS, Köbel M, Mackay H, Huntsman DG. (2011-01-26). Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol. 121(2),407
  15. DeLair D, Oliva E, Köbel M, Macias A, Gilks CB, Soslow RA. (2011-01-01). Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol. 35(1),36
  16. Kalloger SE, Köbel M, Leung S, Mehl E, Gao D, Marcon KM, Chow C, Clarke BA, Huntsman DG, Gilks CB. (2010-12-03). Calculator for ovarian carcinoma subtype prediction. Mod Pathol. 24(4),512
  17. Swenerton KD, Santos JL, Gilks CB, Köbel M, Hoskins PJ, Wong F, Le ND. (2010-08-06). Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Oncol. 22(2),341
  18. Köbel M, Reuss A, Bois AD, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB. (2010-07-13). The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 222(2),191
  19. Alkushi A, Köbel M, Kalloger SE, Gilks CB. (2010-07-01). High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol. 29(4),343
  20. Köbel M, Kalloger SE, Baker PM, Ewanowich CA, Arseneau J, Zherebitskiy V, Abdulkarim S, Leung S, Duggan MA, Fontaine D, Parker R, Huntsman DG, Gilks CB. (2010-07-01). Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol. 34(7),984
  21. Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB. (2010-05-01). Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 29(3),203
  22. Tabrizi AD, Kalloger SE, Köbel M, Cipollone J, Roskelley CD, Mehl E, Gilks CB. (2010-03-01). Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol. 29(2),99
  23. Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM. (2010-02-01). Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol. 220(3),392
  24. Köbel M, Gilks CB, Huntsman DG. (2009-12-15). Adult-type granulosa cell tumors and FOXL2 mutation. Cancer Res. 69(24),9160
  25. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM. (2009-12-10). HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 9(0),433
  26. Kbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. (2009-10-10). Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecol Oncol. 116(1),50
  27. Milne K, Kbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. (2009-07-29). Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 4(7),6412
  28. Shah SP, Koebel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. (2009-06-10). Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 360(26),2719
  29. Terry J, Torlakovic EE, Garratt J, Miller D, Köbel M, Cooper J, Bahzad S, Pilavdzic D, Oʼmalley F, Oʼbrien AE, Sengupta S, Alport E, Têtu B, Knight B, Pettigrew NM, Berendt R, Wolber R, Trotter MJ, Riddell RH, Gaboury L, Elms F, Magliocco A, Barnes P, Gown AM, Gilks CB. (2009-04-09). Implementation of a Canadian External Quality Assurance Program for Breast Cancer Biomarkers: An Initiative of Canadian Quality Control in Immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Appl Immunohistochem Mol Morphol. 17(5),375
  30. Köbel M, Gilks CB, Huntsman DG. (2009-03-12). Dicer and Drosha in ovarian cancer. N Engl J Med. 360(11),1150
  31. Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D. (2009-02-01). The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer. 19(1),58
  32. Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB. (2009-01-09). IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol. 22(3),469
  33. Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB. (2009-01-01). A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. Am J Surg Pathol. 33(1),14
  34. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. (2008-12-02). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5(12),232
  35. Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Köbel M, Kalloger SE, Gilks CB, Watson PH, Nelson BH. (2008-10-15). Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS ONE. 3(10),3409
  36. Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG, Köbel M. (2008-09-01). Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 10(9),1021
  37. Köbel M, Huntsman D, Gilks CB. (2008-08-01). Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med. 22(0),10
  38. Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency. (2008-08-01). Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 39(8),1239
  39. Prentice LM, Klausen C, Kalloger S, Kobel M, McKinney S, Santos JL, Kenney C, Mehl E, Gilks CB, Leung P, Swenerton K, Huntsman DG, Aparicio SA. (2007-11-15). Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med. 5(1),33
Principal Investigators
  • C. Blake Gilks
  • David Huntsman
  • Torsten Nielsen
  • Team
  • Christine Chow
  • Dave Voduc
  • Dongxia (Doris) Gao
  • Jennifer Choo
  • Niki Boyd
  • Samuel Leung
  • Sherman Lau
  • Alumni
  • Alessandro DeLuca
  • Andy Chan
  • Ashish Rajput
  • Blaise Clarke
  • Challayne Smith
  • Cindy Ruttan
  • Diana Ionescu
  • Dmitry Turbin
  • Dustin Thomson
  • Edward Lee
  • Erika Mehl
  • Erika Yorida
  • Hamid Masoudi
  • Jen Born
  • Jenny Cromarty
  • Jon Carrick
  • Krista Marcon
  • Maggie Cheang
  • Makoto Endo
  • Martin Koebel
  • Melinda Miller
  • Nicholas Au
  • Nikita Makretsov
  • Sonja Steigen
  • Steve Kalloger
  • Vlady Pavlova
  • spacer
    spacer
    spacer
    Logo
    spacer
    spacer
    Copyright © 2014 Genetic Pathology Evaluation Centre All Rights Reserved; Last modified June 18, 2014